ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2970

In Idiopathic Retroperitoneal Fibrosis, Persistent FDG PET Uptake Helps Identifying Patients at Risk for Relapse

Gabriel Morin1, Arthur Mageau1, Khadija Benali1, Eve Piekarski1, Remi Bertinchamp1, Quentin Raimbourg1, Jean Francois Alexandra2, Antoine Dossier1, Tiphaine Goulenok1, Damien van Gysel1, Thomas Papo1 and Karim Sacre2, 1Université Paris-Diderot, Paris, France, 2Bichat Hospital, Paris Diderot University, Paris, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Retroperitoneal Fibrosing

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, October 24, 2018

Session Title: 6W021 ACR Abstract: Misc Rheumatic & Inflam DZ II (2970–2975)

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Idiopathic retroperitoneal fibrosis (IRF) is a rare disease characterized by abdominal periaortic fibro-inflammatory tissue. The aim of this study was to evaluate the prognostic value of fibrosis FDG uptake using FDG/PET CT in patients with IRF

Methods: In this monocentric retrospective cohort study, all patients admitted for IRF from January 2009 to December 2017 underwent a FDG/PET CT at diagnosis and during follow up. Metabolic activity assessed by fibrosis FDG uptake was measured by generating a volume of interest to calculate the maximal standardized uptake value (SUVmax). Complete remission was defined by the disappearance of initial symptoms associated with normal CRP, increased/stabilization of eGFR and decreased/stabilization of the retroperitoneal mass on CT-scan. The primary outcome was IRF relapse rate during follow-up

Results: FDG/PET CT was performed at diagnosis, 3.1 [1-8.7] months (i.e 1st evaluation) and 10.4 [4.9-17.5] months (i.e 2nd evaluation) after IRF diagnosis in 23 patients (54.7 [36.9-89] years, 73.9% of men). FDG fibrosis uptake was seen in 23 (100%; SUVmax 6.5 [3.8-11.9]), 16 (69.6%; SUVmax 3.65 [2.1-5.4]) and 12 (52.2%; SUVmax 3.75 [2.7-7.8]) patients at diagnosis, 1st and 2nd evaluation, respectively. All but one patient had received steroids at IRF diagnosis and 21 (91.3%) were in complete remission at both 1st and 2nd evaluation. During a median follow-up period of 38.7 [3-107] months, 6 (26.1%) patients suffered IRF relapse that occurred 15.7 [9.2-42.8] months after diagnosis. Univariate analysis showed that CRP level at diagnosis, complete remission at 1st and 2nd evaluation and fibrosis FDG uptake at 2nd evaluation were associated with IRF relapse. In the multivariable analysis, only fibrosis FDG uptake at 2nd evaluation (p=0.046) was associated with IRF relapse. Sensitivity, specificity, negative predictive value and positive predictive value of fibrosis FDG uptake at 2nd evaluation to predict IRF relapse were respectively 100%, 60%, 100% and 50%. Eventually, patients with fibrosis FDG uptake at 2nd evaluation had a higher recurrence rate during follow up (p=0.047)

Conclusion:

In IRF, fibrosis FDG uptake during follow up is associated with clinical outcome. FDG/PET CT may help to better stratify the risk of relapse in IRF and target immunosuppressive therapy

Characteristic of patients

 

Relapse

(n=6)

No Relapse (n=17)

p

Age, years

53.3 [41.2-61.3]

57.1 [34.4-89]

ns

Men, n (%)

4 (66.7)

13 (76.5)

ns

Biopsy proven, n (%)

3 (50)

7 (41.2)

ns

IgG4, n (%)

1 (16.7)

2 (11.8)

ns

Abdominal pain at diagnosis, n (%)

6 (100)

14 (82.4)

ns

Constitutional symptoms at diagnosis, n (%)

4 (66.7)

9 (52.9)

ns

CRP at diagnosis, mg/L

40 [10-221]

17 [3-40]

0.0251

High CRP level at diagnosis, n (%)

5 (83.3)

7 (41.2)

ns

Serum creatinin at diagnosis, umol/L

143.5 [90-2254]

79 [54-560]

ns

High creatinin level at diagnosis, n (%)

3 (50)

7 (41.2)

ns

FDG-PET fibrosis uptake at diagnosis, n (%)

6 (100)

17 (100)

1

SUVmax at diagnosis

10.1 [5.5-11.9]

5.4 [3.2-10.7]

ns

Steroids at diagnosis, n (%)

6 (100)

16 (94.1)

1

Complete remission at 1st evaluation

4 (66.7)

17 (100)

0.0593

FDG-PET fibrosis uptake at 1st evaluation n (%)

6 (100)

10 (58.8)

ns

SUVmax at 1st evaluation

3.4 [3.1-3.7]

4.1 [2.1-5.4]

ns

Complete remission at 2nd evaluation

4 (66.7)

17 (100)

0.0593

FDG-PET fibrosis uptake at 2nd evaluation n (%)

6 (100)

6 (35.3)

0.0137

SUVmax at 2nd evaluation

5.3 [2.7-7.8]

3.4 [3.2-4.5]

0.08364

Follow up

Length, months

47.9 [26.9-106.9]

33.8 [2.8-71.5]

ns

Cumulative months of steroids

45.5 [26.9-106.9]

23.4 [2.8-56.6]

ns

Steroids withdrawal, n (%)

2 (33.3)

8 (50)

ns

Immunosuppressive drugs at any time, n (%)

4 (66.7)

0

0.0017

Death

0

2 (11.8)

ns

Patients with FDG-PET fibrosis uptake (FDG-PET+) during follow up had higher rates of relapse than patients without FDG-PET fibrosis uptake (FDG-PET-)


Disclosure: G. Morin, None; A. Mageau, None; K. Benali, None; E. Piekarski, None; R. Bertinchamp, None; Q. Raimbourg, None; J. F. Alexandra, None; A. Dossier, None; T. Goulenok, None; D. van Gysel, None; T. Papo, None; K. Sacre, None.

To cite this abstract in AMA style:

Morin G, Mageau A, Benali K, Piekarski E, Bertinchamp R, Raimbourg Q, Alexandra JF, Dossier A, Goulenok T, van Gysel D, Papo T, Sacre K. In Idiopathic Retroperitoneal Fibrosis, Persistent FDG PET Uptake Helps Identifying Patients at Risk for Relapse [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/in-idiopathic-retroperitoneal-fibrosis-persistent-fdg-pet-uptake-helps-identifying-patients-at-risk-for-relapse/. Accessed August 15, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-idiopathic-retroperitoneal-fibrosis-persistent-fdg-pet-uptake-helps-identifying-patients-at-risk-for-relapse/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies